Neratinib
PUMA-NER-5201
Phase 2 small_molecule terminated
Quick answer
Neratinib for Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations is a Phase 2 program (small_molecule) at PUMA BIOTECHNOLOGY, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- PUMA BIOTECHNOLOGY, INC.
- Indication
- Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- terminated